Fusion Antibodies plc (LSE:FAB) has successfully validated its OptiMAL® platform, achieving a major milestone in its collaboration with the U.S. National Cancer Institute (NCI). The validation confirms the platform’s ability to isolate specific antibodies against both protein and peptide targets, significantly broadening its potential applications in therapeutic antibody discovery.
The company is preparing for the commercial launch of OptiMAL® in December 2025, positioning the platform as a next-generation solution in the antibody engineering market. The NCI has expressed interest in extending its partnership with Fusion, reflecting confidence in OptiMAL®’s capabilities and commercial promise.
Despite this scientific progress, Fusion Antibodies continues to face financial challenges, including persistent losses and limited cash flow. Technical indicators point to bearish momentum, and valuation metrics underscore ongoing unprofitability. Nevertheless, the company’s pipeline and partnerships offer a foundation for potential long-term recovery.
More about Fusion Antibodies plc
Fusion Antibodies plc is a Belfast-based contract research organization specializing in advanced antibody engineering services for therapeutic and diagnostic use. Founded in 2001 as a spin-out from Queen’s University Belfast, the company provides end-to-end services in antibody generation, development, characterization, and optimization.
Fusion’s global client base includes eight of the world’s top ten pharmaceutical companies, and it continues to focus on accelerating biologic drug development through innovative technologies such as its OptiMAL® platform.
Leave a Reply